Best Urologists in Texas

Houston Methodist | Houston, TX | Urologic oncology, bladder cancer

Dr. Kamat is a professor of urology in Houston with a long track record in bladder cancer research and clinical trial leadership. He treats patients across the full spectrum of urologic cancer, with particular depth in non-muscle-invasive bladder cancer — the form where tumors have not yet grown into the bladder wall and where decisions about surveillance, BCG immunotherapy, and surgery can get complicated.

His published research, which spans more than 1,000 works over his career, has been cited tens of thousands of times by other bladder cancer researchers. If you have been diagnosed with bladder cancer and are trying to decide between close surveillance, intravesical therapy, or removal of the bladder, his practice is one where you are seeing a physician who has helped write the questions everyone else is trying to answer.

Houston Methodist Hospital | Houston, TX | Female pelvic medicine, urinary incontinence

Dr. Kobashi is a urologist at Houston Methodist whose clinical focus is female pelvic medicine and reconstructive surgery. She treats women with urinary incontinence, pelvic organ prolapse, recurrent urinary tract infections, and complications from prior mesh surgery — a population whose symptoms often go underdiagnosed for years before reaching a specialist.

Her 2003 paper in The Journal of Urology on management of vaginal mesh sling erosion was a turning point ¹. At the time, the default response to any mesh erosion was full surgical removal of the sling. Dr. Kobashi and her team reported four cases where watchful management led to spontaneous healing while preserving continence, a result that gave surgeons a less invasive option to consider first. A 2003 companion paper catalogued perioperative complications across the first 140 polypropylene slings her team placed, shaping how surgeons counsel patients on risk ³. More recently, she was senior author on a 2021 analysis from the Urologic Diseases in America Project that pinned down how many American women actually live with urinary incontinence ². She has also contributed to trials of overactive bladder medications including solifenacin and darifenacin ⁴⁵.

Baylor St. Luke's Medical Center | Houston, TX | Urologic oncology, bladder cancer

Dr. Lerner is a professor of urology at Baylor St. Luke's Medical Center in Houston, with a clinical practice centered on bladder, kidney, and prostate cancer. He has spent decades leading and contributing to national cooperative group trials, which is how new treatment protocols for bladder cancer move from idea to standard of care.

His research output — more than 700 published works — reflects a career spent at the center of bladder cancer science. For patients with muscle-invasive bladder cancer weighing whether to pursue radical cystectomy, bladder-preserving chemoradiation, or enrollment in a clinical trial, his practice is one where the physician has helped design many of the trials that created today's options.

Baptist Hospitals of Southeast Texas | San Antonio, TX | General urology, prostate cancer

Dr. Saltzstein practices in San Antonio with a general urology focus that includes prostate cancer management and overactive bladder care. He has been an active site investigator in industry-sponsored trials, which gives his patients access to new drugs before they reach general availability.

He contributed to the HERO trial, a 2020 New England Journal of Medicine study showing that oral relugolix — a pill-based androgen-deprivation therapy for advanced prostate cancer — suppressed testosterone faster than the standard injection and cut major cardiovascular events by 54 percent ⁶. For men with advanced prostate cancer and existing heart disease, that finding changed the conversation about which hormone therapy to start with. He also contributed to foundational overactive bladder research, including the OBJECT study comparing extended-release oxybutynin and tolterodine ⁸¹⁰, and trials of transdermal oxybutynin ⁹ and once-daily controlled-release oxybutynin ⁷ — drugs that patients are still prescribed today.

Houston Methodist Hospital | Houston, TX | General urology

Dr. Goldfarb is a urologist at Houston Methodist Hospital whose practice covers kidney stones, urinary tract problems in pregnancy, prostate conditions, and general urologic care. His publication history is smaller than some of his peers but includes early contributions on how to manage urologic complications safely in specific high-risk populations.

He was first author on a 1989 paper in The Journal of Urology on managing acute kidney swelling during pregnancy with ureteral stenting, which flagged how the calcium-rich environment of pregnancy accelerates stone formation on stents and argued for a more conservative protocol ¹¹. He has also contributed to work on kidney cancer genetics, including a paper identifying a chromosomal translocation linked to hereditary clear cell renal cell carcinoma ¹⁴, and on unusual infections including a case of prostatic abscess from disseminated histoplasmosis in an immunocompromised patient ¹⁵. His newer work includes a multicenter study of a non-invasive body contouring device ¹² and earlier research on MRI localization of adrenal tumors ¹³.

Houston Methodist Hospital | Houston, TX | Urologic oncology, outcomes research

Dr. Satkunasivam practices at Houston Methodist Hospital with affiliations at Houston Methodist Baytown and Houston Methodist Clear Lake. His clinical focus is urologic oncology — bladder, kidney, and prostate cancer — and his research sits at the intersection of surgical outcomes and health services research.

He was senior author on a 2017 BMJ study of more than 100,000 patients that found female surgeons had slightly better postoperative outcomes than male surgeons across 25 common operations ¹⁶. A 2021 JAMA Surgery follow-up showed that female patients treated by male surgeons had worse outcomes, a finding that raised serious questions about how surgeon-patient match affects operating-room care ¹⁷. He also contributed to a 2017 Journal of Clinical Oncology analysis comparing radical cystectomy with bladder-sparing trimodal therapy — surgery versus radiation plus chemotherapy — for muscle-invasive bladder cancer ¹⁸, giving patients weighing organ preservation a real evidence base. His published work also spans immunotherapy response by sex ¹⁹ and a meta-analysis comparing surgery and radiotherapy for localized prostate cancer ²⁰.